Sprint Q3: VADA progress and a new CEO - Redeye

Redeye provides a brief comment on Sprint Bioscience’s Q3 report. We will soon return with a more extensive take on the case in light of the VADA licensing agreement and where we will likely increase our base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/949923/sprint-q3-vada-progress-and-a-new-ceo?utm_source=finwire&utm_medium=RSS